In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae

Clinical Microbiology and Infection

Volumn 20, Issue 11, 2014, Pages O831-O839

  Harada, Y ^a   Morinaga, Y ^a   Kaku, N ^a   Nakamura, S ^a   Uno, N ^a   Hasegawa, H ^a   Izumikawa, K ^a   Kohno, S ^a,b   Yanagihara, K ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Extended spectrum lactamase; Inoculum effect; Klebsiella pneumoniae; Meropenem; Piperacillin tazobactam; Pneumonia

Indexed keywords

BETA LACTAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CILASTATIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; BACTERIOSTASIS; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GENOTYPE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INOCULATION; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMONIA, BACTERIAL; SURVIVAL;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE; MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MALE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; SURVIVAL ANALYSIS; THIENAMYCINS;

EID: 84917735893     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12677     Document Type: Article

References (41)

1. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-37.
2. Peralta G, Lamelo M, Alvarez-Garcia P et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. Bacteremia. A multicentric cohort study. BMC Infect Dis 2012; 12: 245.
3. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
4. Feldman C, Smith C, Levy H, Ginsburg P, Miller SD, Koornhof HJ. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect 1990; 20: 21-31.
5. Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 1998; 38: 119-132.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. M100-s21. Wane, PA: CLSI, 2011.
7. Doern GV, Tubert T. Effect of inoculum size on results of macrotube broth dilution susceptibility tests with branhamella catarrhalis. J Clin Microbiol 1987; 25: 1576-1578.
8. Syriopoulou VP, Scheifele DW, Sack CM, Smith AL. Effect of inoculum size on the susceptibility of haemophilus influenzae b to beta-lactam antibiotics. Antimicrob Agents Chemother 1979; 16: 510-513.
9. Brook I. Inoculum effect. Rev Infect Dis 1989; 11: 361-368.
10. Goldstein EJ, Citron DM, Cherubin CE. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the bacteroides fragilis group. Antimicrob Agents Chemother 1991; 35: 1868-1874.
11. Soriano F, Coronel P, Gimeno M, Jimenez M, Garcia-Corbeira P, Fernandez-Roblas R. Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, haemophilus influenzae, and neisseria meningitidis. Eur J Clin Microbiol Infect Dis 1996; 15: 761-763.
12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-2803.
13. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 2004; 50: 229-230.
14. Perez F, Bonomo RA. Can we really use ss-lactam/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing bacteria? Clin Infect Dis 2012; 54: 175-177.
15. Leleu G, Kitzis MD, Vallois JM, Gutmann L, Decazes JM. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the tem-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother 1994; 38: 195-199.
16. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-3554.
17. Segatore B, Setacci D, Perilli M et al. Antimicrobial susceptibility of clinical isolates of enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes. Int J Antimicrob Agents 2004; 23: 480-486.
18. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and beta-lactamase activity in ampc- and extended-spectrum beta-lactamase (esbl)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using nccls esbl methodology. J Clin Microbiol 2004; 42: 269-275.
19. Burgess DS, Hall RG 2nd. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2004; 49: 41-46.
20. Docobo-Perez F, Lopez-Cerero L, Lopez-Rojas R et al. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum beta-lactamase (esbl)-producing and non-esbl-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 2013; 57: 2109-2113.
21. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2007; 51: 1481-1486.
22. Harada Y, Morinaga Y, Yamada K, Migiyama Y, Nagaoka K. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli in a Japanese tertiary hospital. J Med Microb Diagn 2013; 2: 3.
23. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007; 60: 1395-1397.
24. Maeda TK, Matsushita K. Pharmacokinetic study of tazobactam/piperacillin in experimental animals. Chemotherapy 1994; 42: 206-216.
25. Lee HC, Chuang YC, Yu WL et al. Clinical implications of hypermuco viscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteraemia. J Intern Med 2006; 259: 606-614.
26. Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med 2004; 199: 697-705.
27. Fukasawa M, Sumita Y, Harabe ET et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase i. Antimicrob Agents Chemother 1992; 36: 1577-1579.
28. Yanagihara K, Seki M, Cheng PW. Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am J Respir Cell Mol Biol 2001; 24: 66-73.
29. EUCAST. Rationale for the eucast clinical breakpoints, version 1.0. Piperacillin-tazobactam. European committee on antimicrobial susceptibility testing, 2010. Available from: http://www.eucast.org/documents/rd/ (last accessed 30 May 2014).
30. EUCAST. Rationale for the eucast clinical breakpoints, version 1.5. Meropenem. European committee on antimicrobial susceptibility testing, 2009. Available from: http://www.eucast.org/documents/rd/ (last accessed 30 May 2014).
31. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF. In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and klebsiella spp. Resistant to oxyimino cephalosporins. Antimicrob Agents Chemother 1995; 39: 1187-1190.
32. Bedenic B, Beader N, Zagar Z. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing shv extended-spectrum beta-lactamases. Clin Microbiol Infect 2001; 7: 626-635.
33. Kang CI, Pai H, Kim SH et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated ampc-type beta-lactamase. J Antimicrob Chemother 2004; 54: 1130-1133.
34. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing enterobacteriaceae: mic matters. Clin Infect Dis 2013; 56: 488-495.
35. Jacoby GA, Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990; 34: 858-862.
36. Rebuck JA, Olsen KM, Fey PD, Bergman KL, Rupp ME. In vitro activities of parenteral beta-lactam antimicrobials against tem-10-, tem-26- and shv-5-derived extended-spectrum beta-lactamases expressed in an isogenic Escherichia coli host. J Antimicrob Chemother 2000; 46: 461-464.
37. Bonnet R. Growing group of extended-spectrum beta-lactamases: the ctx-m enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
38. Lopez-Cerero L, Picon E, Morillo C et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 2010; 16: 132-136.
39. del Mar Tomas M, Cartelle M, Pertega S et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005; 11: 540-546.
40. Pena C, Guzman A, Suarez C et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007; 51: 1967-1971.
41. Kyrgidis A, Tzellos TG, Toulis K, Arora A, Kouvelas D, Triaridis S. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients. Curr Clin Pharmacol 2013; 8: 124-134.